EPR Properties vs Pfizer Inc — how do they compare? EPR Properties trades at $60 (market cap $4.58B), while Pfizer Inc trades at $26.55 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 33.1× EPR Properties's market cap, and Pfizer Inc pays the higher dividend (6.46%). Which is the better fit depends on your goals.
| EPR | PFE | |
|---|---|---|
Market Cap | $4.58B | $151.73B |
Sector | Real Estate | Health |
52-Week High | $64.32 | $28.56 |
52-Week Low | $48.71 | $23.60 |
Enterprise Value | $8.09B | $203.22B |
Dividend Yield | 6.22% | 6.46% |
Volume | — | 29,869,932 |
Signals from Pluang's Aura AI — not financial advice
EPR Properties trades at $62.20, up 1.4% today, with a neutral technical signal and mixed earnings history including a recent Q2 2026 beat. The company shows strong profitability with a 91.41% gross margin and raised 2026 FFO guidance, supported by a new $1.6 billion credit facility announced on July 20, 2026. Key resistance is at $63, with support at $61.
Outlook is cautiously positive given analyst consensus of $65.30 price target and dividend stability, but risks include declining net income margins and high valuation multiples. Investment appeal hinges on execution of acquisition strategy amid economic sensitivity.
Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.
Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.
Trailing returns across standard periods
Latest headlines on both assets
EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.
Read more on EPR →Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →